	US 11,806,401 B2
	Prevention of drug-induced atrio-ventricular block
Lawrence Helson, Quakertown, PA (US); and Annie Bouchard, Stoke (CA)
Assigned to Signpath Pharma, Inc., Sandy, UT (US)
Filed by SignPath Pharma Inc., Sandy, UT (US)
Filed on Apr. 24, 2017, as Appl. No. 15/494,932.
Claims priority of provisional application 62/328,307, filed on Apr. 27, 2016.
Prior Publication US 2017/0312366 A1, Nov. 2, 2017
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/127 (2006.01); A61K 47/24 (2006.01); A61K 31/685 (2006.01); A61K 9/00 (2006.01); A61K 31/137 (2006.01); A61K 31/277 (2006.01); A61K 31/4709 (2006.01); A61K 49/00 (2006.01)

CPC A61K 47/24 (2013.01) [A61K 9/0053 (2013.01); A61K 9/127 (2013.01); A61K 31/137 (2013.01); A61K 31/277 (2013.01); A61K 31/4709 (2013.01); A61K 31/685 (2013.01); A61K 49/0008 (2013.01)]

5 Claims

1. A method of treating a drug-induced atrioventricular (AV) block consisting of:

identifying a subject in need of a drug therapy, wherein the drug therapy is contraindicated because it causes a drug-induced atrioventricular (AV) block and the drug therapy consists of a therapeutically effective amount of fingolimod and verapamil that causes AV block; and

providing the subject with the therapeutically effective amount of fingolimod and verapamil, with a single dose of 1 mg/kg of 14:0 lysophosphatidylglycerol sufficient to reduce or eliminate the AV block for at least 1 to 8 hours, wherein the AV block is a third-degree AV block; and

reducing or eliminating the drug-induced AV block by 90, 95, or 100%, wherein the lipid and drug combination are co-administered orally, enterally, parenterally, intravenously, or intraperitoneally.